Pulmatrix (NASDAQ:PULM) and Urogen Pharma (NASDAQ:URGN) Head-To-Head Comparison

Urogen Pharma (NASDAQ:URGN) and Pulmatrix (NASDAQ:PULM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Urogen Pharma and Pulmatrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Pulmatrix	N/A	-125.65%	-95.19%

Risk and Volatility

Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.

Insider and Institutional Ownership

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Urogen Pharma and Pulmatrix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79 million	18.36	-$153.49 million	($1.98)	-20.82
Pulmatrix	$7.81 million	0.78	-$5.16 million	($1.10)	-1.52

Pulmatrix has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Urogen Pharma and Pulmatrix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1	1	8	0	2.70
Pulmatrix	1	0	0	0	1.00

Urogen Pharma presently has a consensus price target of $52.38, suggesting a potential upside of 27.03%. Given Urogen Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Pulmatrix.

Summary

Urogen Pharma beats Pulmatrix on 9 of the 14 factors compared between the two stocks.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.